Select Equity Group L.P. Cuts Holdings in Certara, Inc. (NASDAQ:CERT)

Select Equity Group L.P. trimmed its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 11.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 172,488 shares of the company’s stock after selling 22,755 shares during the period. Select Equity Group L.P.’s holdings in Certara were worth $1,837,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Blue Trust Inc. boosted its stake in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Certara by 3.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock valued at $253,000 after purchasing an additional 823 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after buying an additional 1,047 shares during the period. Bank of Montreal Can lifted its holdings in shares of Certara by 9.1% during the 4th quarter. Bank of Montreal Can now owns 19,943 shares of the company’s stock valued at $212,000 after buying an additional 1,670 shares during the period. Finally, O Shaughnessy Asset Management LLC lifted its holdings in shares of Certara by 20.5% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company’s stock valued at $138,000 after buying an additional 2,202 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CERT has been the topic of several research analyst reports. Barclays raised Certara from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $11.00 to $14.00 in a report on Thursday, May 8th. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, April 11th. Stephens reissued an “overweight” rating and set a $17.00 price target on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target on the stock. Finally, William Blair reissued a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.67.

Certara Price Performance

Shares of Certara stock opened at $11.88 on Friday. Certara, Inc. has a one year low of $8.64 and a one year high of $17.76. The stock’s fifty day moving average is $11.72 and its 200 day moving average is $11.73. The stock has a market cap of $1.93 billion, a P/E ratio of -59.40, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara (NASDAQ:CERT) last announced its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $106.00 million for the quarter, compared to analysts’ expectations of $104.44 million. During the same period last year, the firm earned $0.10 EPS. Certara’s revenue for the quarter was up 9.7% compared to the same quarter last year. Sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.